showed a trendp > 0.05
Repeated treatment with 200 mg/kg SZ-A increased fecal TDCA and TLCA content ( p < 0.05, Figure A,B) and elevated the TMCA content by 103.8% ( p > 0.05, Figure C) compared to the Con group. It also decreased the content of 7-KDCA and 12-KLCA ( p < 0.05, Figure D,E) and showed a trend toward lowering TCDCA and CDCA contents ( p > 0.05, Figure F,G).